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Table 1: Descriptive statistics for the patients included in the study 26 
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ABSTRACT 38 
Number of days spent in acute hospitals (DAH) at the end of life is regarded as an important care 39 
quality indicator for cancer patients. We analysed DAH during 90 days prior to death in patients from 40 
four Swiss cantons. Claims data from an insurance provider with about 20% market share and 41 
patient record review identified 2086 patients as dying of cancer. We calculated total DAH per 42 
patient. Multivariable generalised linear modelling served to evaluate potential explanatory 43 
variables. Mean DAH was 26 days. In the multivariable model, using complementary and alternative 44 
medicine (DAH = 33.9; +8.8 days compared to non-users) and canton of residence (for patient 45 
receiving anti-cancer therapy, Zürich DAH = 22.8 versus Basel DAH = 31.4; for other patients, Valais 46 
DAH = 22.7 versus Ticino DAH = 33.7) had the strongest influence. Age at death and days spent in 47 
other institutions were additional significant predictors. DAH during the last 90 days of life of cancer 48 
patients from four Swiss cantons is high compared to most other countries. Several factors influence 49 
DAH. Resulting differences are likely to have financial impact, as DAH is a major cost driver for end-50 
of-life care. Whether they are supply- or demand-driven and whether patients would prefer fewer 51 
days in hospital remains to be established. 52 
 53 
INTRODUCTION 54 
More days in hospital, frequent hospitalisations and a high proportion of deaths in hospital are 55 
considered poor quality of care indicators in end-of-life cancer patients (Earle et al. 2003; Grunfeld 56 
et al. 2006, 2008; Setoguchi et al. 2008). The length of stay in acute care hospitals of end-of-life 57 
cancer or other patients is known to be dependent on demographical (Smith et al. 2009) and 58 
geographical (Wennberg et al. 2004) factors, and the place of death differs considerably between 59 
European countries (Cohen et al. 2010; Gao et al. 2013; Matter-Walstra et al. 2014). In a previous 60 
study of end-of-life care of cancer patients in four Swiss cantons, we showed that cancer-specific 61 
delivery of care and hospitalisation rates were dependent on both demographical and geographical 62 
factors (Matter-Walstra et al. 2014). In a follow-up in-depth analysis of the influence of the treating 63 
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hospitals, we established that the hospital type (Fos 2006) had a significant effect on the delivery of 64 
care (Matter-Walstra et al. 2015). Being hospitalised in a university hospital in Switzerland 65 
significantly increased the odds of receiving any kind of cancer-related therapy (two of five Swiss 66 
university hospitals were in the catchment area of our study).  67 
Here, we focus on the number of days cancer patients spend in acute hospitals (DAH) during the last 68 
90 days of life. DAH is important: (1) because it is an important indicator of the quality of end-of-life 69 
care, and an increasing number of days spent in hospital is regarded as associated with decreased 70 
quality of life (Earle et al. 2003; Grunfeld et al. 2006, 2008; Setoguchi et al. 2008); and (2) because 71 
inpatient care may account for the largest proportion of total costs that cancer patients incur 72 
(Langton et al. 2014). Patient-determined factors, such as the choice of insurance package or use of 73 
specific healthcare provision like complementary and alternative medicine (CAM) therapies, may 74 
also be associated with DAH. For instance, the consumption of mistletoe (Van Der Weg & Streuli 75 
2003) may reduce the use of conventional therapies in cancer patients (Heusser et al. 2006; Bar-Sela 76 
et al. 2013). The use of mistletoe and other CAM therapies is widespread in Switzerland (Wolf et al. 77 
2006); however, their effect on length of stay of cancer patients has yet to be determined.  78 
The aim of this study was to investigate the causes of disparities in end-of-life care of cancer patients 79 
in four Swiss cantons, in terms of DAH, and discuss the possible economic impact. In the current 80 
study, the effects of demographical, geographical and patient-determined factors on DAH were 81 
investigated.  82 
 83 
METHODS 84 
Study population 85 
The study population and data collection methods are described in detail in our previous publication 86 
(Matter-Walstra et al. 2014). Briefly, the study population included patients 20 years or older at time 87 
of cancer diagnosis who died between 2006 and 2008, lived in one of the participating Swiss 88 
cantons, and were Helsana Group insurance company customers for at least 1 year prior to death. In 89 
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total, 3809 patients from the Cantons of Basel (BS, German speaking, one university hospital), Ticino 90 
(TI, Italian speaking, no university hospital), Valais (VS, German/French speaking, no university 91 
hospital) and Zürich (ZH, German speaking, one university hospital) were eligible and included. In the 92 
30 days prior to death, 2608 (68.5%) of these patients were hospitalised in acute care hospitals. 93 
Inpatient information was available for 2494 (96%) of the 2608 patients, and 2086 (83.6%) had a 94 
cancer-related hospitalisation. Hospitalisations were defined as cancer-related if there was: a 95 
primary admission diagnosis indicative of cancer; and/or the patient had cancer-related symptom(s) 96 
or diseases; and/or there was a non-cancer-related reason for admission but the patient had 97 
ongoing active cancer according to the patient records. Subsequent analyses are based on these 98 
2086 patients. 99 
 100 
Outcome measure 101 
For all patients with cancer-related hospitalisations, the total number of DAH during the last 90 days 102 
of life, potentially representing more than one hospitals/hospitalisations, was calculated. The 103 
number of days included the day of admission and day of discharge, each counted as one. 104 
 105 
Explanatory variables 106 
The effect of the following variables on DAH was investigated: 107 
1. Patient age at death, gender and cancer type (colon, haematological, lung, breast, prostate 108 
and all others combined). 109 
2. Type of hospital supplementary insurance (HSI): no HSI = basic (mandatory health insurance, 110 
hospitalisation only on general ward in predefined hospitals within canton of residence); 111 
ECO = basic HSI (hospitalisation on general ward in any hospital in Switzerland); SP+P = semi-112 
private or private (hospitalisation in double or single bedroom in any hospital in 113 
Switzerland). 114 
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3. Use of CAM therapies. Patients were labelled as a CAM patient when: treated with mistletoe 115 
(according to the anatomic therapeutic chemical code or pharmacode); consulted a CAM 116 
physician (homoeopath, anthroposophic physician, neural therapist or traditional Chinese 117 
medicine practitioner including acupuncture, as designated by the insurance claim); or was 118 
treated as an inpatient and/or outpatient in a CAM hospital (five in total; 119 
http://vitagate.ch/sites/default/files/wem_files/Therapieformen/Leitlinien_Dakomed.pdf) 120 
during the last year of life. Otherwise, the patient was labelled as a conventional medicine 121 
(COM) patient. 122 
4. Whether or not the patients received any kind of anticancer therapy (ACT; chemotherapy, or 123 
radiotherapy, see Matter-Walstra et al. 2014) during the last 90 days of life. 124 
5. Whether or not the patient died while in an acute hospital. 125 
6. The number of days spent in other institutions (nursing homes, rehabilitation, geriatric or 126 
psychiatric institutions). 127 
 128 
Statistical analyses 129 
Patient characteristics and categorical explanatory values were described using frequency tables. 130 
The 95% confidence intervals for the mean and median were calculated for age, DAH and days spent 131 
in other institutions (DOI). 132 
Univariable associations between potential explanatory variables and DAH were analysed using a 133 
generalised linear model with a Poisson distribution and a logarithmic link function (Proc Genmod 134 
SAS®) (Kianifard & Gallo 1995). In the log-linear model, the literal interpretation of the estimated 135 
coefficient ?̂?𝛽 bis that a one-unit increase in an explanatory variable will produce an expected 136 
increase in log DAH of ?̂?𝛽 units. In terms of DAH itself, this means that the expected DAH value is 137 
multiplied by ?̂?𝛽. For clarity, we also report estimated DAH results. 138 
Thereafter, a multivariable generalised linear model was developed using a backward selection 139 
method and only including explanatory variables with P < 0.05. All possible interactions were tested, 140 
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and interactions with P < 0.05 were included in the model. The final model used a weighting scheme 141 
for the computation of least squares means coefficients to compensate for unbalanced covariates 142 
such as CAM/COM users (12% versus 88% of the patients). The standard least squares means have 143 
equal coefficients across classification effects; however, the weighting option changes these 144 
coefficients to be proportional to those found in the data set. This adjustment is reasonable when 145 
inferences need to be applied to a population that is not necessarily balanced but has the margins 146 
observed in the data set. To illustrate the impact of the observed effect estimates, DAH values are 147 
reported for different scenarios (i.e. combinations of parameter values for gender, ACT, CAM use 148 
and canton of residence). The results of the multivariable generalised linear model are regarded as 149 
the main results of the analysis. 150 
Statistical analyses were performed with SAS® version 9.3 (SAS, Cary, NC, USA). 151 
 152 
RESULTS 153 
Descriptive statistics 154 
The overall mean age at death of the 2086 eligible patients (Matter-Walstra et al. 2015) was 72.4 155 
years (Table 1). The majority of patients were men (54.8%, Table 1). Lung cancer, residence in the 156 
Canton of Zürich and basic (ECO) supplementary hospital insurance were most frequent. Forty-nine 157 
per cent of patients had received any kind of ACT during the 90 days prior to death, and 79.82% died 158 
in an acute hospital. Patients were hospitalised in 83 different hospitals of all types, from university 159 
hospitals to small regional service hospitals and small specialised hospitals (Fos, 2006). On average, 160 
patients had 2.3 (median 2.0) hospitalisations during the 90 days prior to death, and 35.1% had only 161 
one hospitalisation. 162 
Of all patients, 11.6% were classified as CAM users (see Table 2 for all data by canton). CAM patients 163 
were more often female and had breast cancer, had semi-private or private HSI and received anti-164 
cancer therapies slightly more frequently than COM patients (Fig. 1). 165 
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There was a minor decrease in DAH with increasing age, while DOI increased markedly with 166 
increasing age (Fig. 2). On average, lung cancer patients and patients who lived in the Canton of 167 
Zürich, had received ACT or were classified as CAM users were younger. The overall mean DAH was 168 
26.4 days (95% CIs 3.0–63.0, median 22.0; Table 3). The highest DAH was seen in the Canton of Basel 169 
(mean 31.1 days, 95% CIs 28.4–33.7, median 27 days), which was almost 7 days longer than in the 170 
Canton of Valais, which had the lowest DAH (23.5 days, 95% CIs 20.5–26.5, median 19.0 days). The 171 
largest difference in DAH of 8.5 days was seen between COM (mean 25.4 days, 95% CIs 24.6–26.3, 172 
median 22.0 days) and CAM (mean 33.9 days, 95% CIs 31.2–36.6, median 30.0 days) patients. 173 
 174 
Uni- and multivariable (regression) models 175 
Univariable modelling (Table 4) did not show a significant effect of cancer type, HSI type or receiving 176 
ACT on DAH. The most significant effect was seen for CAM users (33.9 DAH versus 25.4 DAH for COM 177 
patients; P < 0.0001), resulting in an increase in DAH of 33% (mean difference in DAH 8.5 days), 178 
followed by canton of residence with a difference in DAH of 6.7 days between BS (31.1 DAH) and ZH 179 
(24.3 DAH; 28% increase compared to ZH, P < 0.001). 180 
In the multivariable model, the use of CAM therapies and canton of residence again showed the 181 
strongest influence on DAH. Use of CAM therapies was associated with a DAH increase by 35% (P < 182 
0.0001), from 25.1 (COM) to 33.9 (CAM) days. The effect of canton of residence depended on 183 
whether or not the patients received ACT (significant interaction between canton and ATC). The 184 
largest difference in DAH was seen in patients not receiving ATC, between cantons TI (33.7 days) and 185 
ZH (24.4 days; increase by 39%; P < 0.001; Table 5). Furthermore, gender (female versus male, 10% 186 
increase for women), age at death (0.5% decrease in DAH per increasing year), DOI (0.24% decrease 187 
in DAH per increasing day spent in other institutions) had a significant effect on DAH. The effect of 188 
receiving ACT was dependent on the canton of residence. While those in TI and ZH receiving ACT had 189 
reduced DAH, BS and VS residents had increased DAH (Fig. 3 and Table 5). 190 
 191 
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DISCUSSION 192 
High numbers of days spent in acute hospitals, a high frequency of hospitalisations, and dying while 193 
in hospital all are regarded as indicators of decreased quality of care at the end of life (Earle et al. 194 
2003; Grunfeld et al. 2006, 2008; Setoguchi et al. 2008; Langton et al. 2014). Here, we show that the 195 
number of days patients with cancer spend in acute hospitals during the last 90 days of life is not 196 
only strongly dependent on the canton of residence but also increases in patients using CAM 197 
therapies during their last year prior to death. While age (decreasing DAH with increasing age), 198 
gender (men having lower DAH than women), receiving ACT (direction of effect depending on 199 
canton of residence) and days spent in other institutions (decreasing DAH with increasing numbers 200 
of days spent in other institutions) played a lesser (but still significant) role, insurance status and 201 
cancer type had no significant influence on DAH. 202 
Sessa et al. (1996) reported that cancer patients in southern Switzerland stayed a median of 24 days 203 
in acute hospitals during the last 3 months prior to death, 75% had one or two hospitalisations, and 204 
65% died while in an acute hospital. In our analysis of a southern canton (Ticino), there were slightly 205 
higher numbers of DAH and almost 20% higher rates of dying in an acute hospital. This is in contrast 206 
to the general observation that DAH in Switzerland decreased between 1998 and 2010 (Roth & Roth 207 
2012). 208 
A comparison of our data and international data is difficult, since DAH over the last 90 days of life is 209 
not always given or the patient population is different (Langton et al. 2014). In addition, healthcare 210 
system differences are difficult to incorporate. Braga et al. (2007), in a single institution study in 211 
Portugal of patients with solid tumours, found that the median DAH during the last 3 months of life 212 
was 16. In a Belgian study (Gielen et al. 2010), the median DAH during the last 6 months prior to 213 
death in cancer patients was 18–21 days (except patients 90+), which is lower than our reported 214 
median of 22 days during the last 3 months of life. Our reported percentage of cancer patients dying 215 
while in an acute hospital (almost 80%) is much higher than other studies in western countries 216 
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(Smith et al. 2009; Setoguchi et al. 2010; Gonsalves et al. 2011; Teno et al. 2013) and similar to, but 217 
still higher than, deaths in acute hospitals in Taiwan (Tang et al. 2009). 218 
One of the reasons for the high DAH seen in Switzerland may be that many acute care hospitals 219 
provide palliative care beds, while only few institutions solely focusing on palliative care or hospices 220 
are available (Eychm€uller & Raemy-Bass 2001). The available claims data did not allow us to 221 
differentiate between hospitalisations with palliative intention and hospitalisations for other (acute) 222 
reasons. Therefore, part of the DAH observed may have been with palliative intent, and might not 223 
have been counted as DAH in other countries. Additional reasons for the higher DAH seen in 224 
Switzerland in comparison with other European countries may be economic or cultural. Swiss 225 
patients may have a more positive perception of being hospitalised and dying in hospital, and may 226 
regard this as an indicator of good quality care. Societal wealth and affordability, demand side 227 
factors and supply side factors such as financial incentives on the side of the healthcare providers 228 
may play a role. 229 
As well as the generally higher DAH and dying in an acute hospital for Swiss patients, a large and 230 
significant difference in DAH between the four cantons was observed (difference in mean DAH of 7.5 231 
days) that remained after correction for other explanatory variables. Plausible but difficult to verify 232 
reasons may be the structures of cantonal healthcare systems, differing cultural attitudes between 233 
cantons, or different financial incentives. For example, there are large differences in acute bed 234 
density and hospitalisation rates between Swiss cantons, with cantons BS and TI being among the 235 
highest ranking for both parameters (Fos, 2013a,b). Our observed DAH for the cantons follow the 236 
same pattern, however data for more cantons would be required to substantiate this relationship. 237 
One noticeable finding was that insurance status has no significant influence on DAH. However, we 238 
grouped patients with semi-private and private insurance together in order to be able to work with 239 
sufficiently sized groups. Separating these two insurance types would be relevant in order to 240 
investigate whether patients with private and semi-private insurance may show different patterns in 241 
terms of DAH. For this, however, a larger data set would be required. 242 
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The other main observation was the statistically highly significant difference in DAH between CAM 243 
and COM patients, with CAM patients having a median of 7 days more DAH. In one randomised 244 
controlled study, the use of mistletoe reduced hospitalisation rates in lung cancer patients (Bar-Sela 245 
et al. 2013). In addition, several non-randomised controlled studies with mistletoe report a 246 
reduction in ACT-induced adverse events (Bock et al. 2004; Augustin et al. 2005; Friedel et al. 2009), 247 
which might also be associated with fewer and/or shorter hospitalisations. These results are in 248 
contrast to our findings. It may be that CAM patients tend to try all possible treatment options, 249 
thereby requiring more days in hospital, which is possibly reflected by their more frequent semi-250 
private or private HSI. 251 
This study has some weaknesses and limitations. First, the definition of cancer-related 252 
hospitalisation was based on patients with a hospitalisation during the month prior to death 253 
(Matter-Walstra et al. 2014, 2015). Patients who died with cancer but had no hospitalisation(s) 254 
during their final month were not included because no direct information on the presence of active 255 
cancer was available from patient records. This may have resulted in over- or underestimation of 256 
DAH over the last 90 days of life, since patients dying of cancer but with a hospitalisation during the 257 
30–90 days prior to death could not be included. Including all patients (as previously Matter-Walstra 258 
et al. 2014), however, might have resulted in underestimation of effect due to including patients not 259 
dying from cancer. Second, the identification of CAM patients was limited to only those therapies 260 
reimbursed by the compulsory insurance. In addition, mistletoe was only included in the ambulatory 261 
care setting, since information on inpatient-administered mistletoe is not documented in the 262 
Helsana database. Therefore, the number of CAM patients was lower than expected (Molassiotis et 263 
al. 2005; Heusser et al. 2006; Adams & Jewell 2007). It is likely that the real CAM population was 264 
larger than that identified. Finally, and notwithstanding the fact that Helsana is one of the largest 265 
insurance companies in Switzerland with 1.28 million customers and covering about 20% of the 266 
Swiss population in 2006, this study relies only on data from one insurance company and four out of 267 
26 cantons. On average, Helsana serves an older population then the general Swiss population 268 
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(Achermann et al. 2011). As intensity of care decreases with age (Matter-Walstra et al. 2014, 2015), 269 
DAH in Switzerland may be even higher than reported here. Including data from more insurance 270 
companies and more cantons, especially ones with large rural and mountain regions and purely 271 
French-speaking cantons, would be desirable since regional differences in supply and utilisation of 272 
healthcare have been described for Switzerland (Klauss et al. 2005; Busato et al. 2010; Ess et al. 273 
2011). We could not investigate the impact of rural versus urban borough type as the proportion of 274 
patients living in a rural borough was only 8% (Matter-Walstra et al. 2014). Finally, our analyses 275 
focused on the total number of days in hospital. As many patients had several episodes of 276 
hospitalisation in different hospitals, we could not include hospital type as a covariate in our 277 
analyses or distinguish effects of public versus private hospitals (as few as 35% of the patients had 278 
one hospitalisation only). 279 
In conclusion, this study shows that cancer patients in four Swiss cantons spent more days in acute 280 
hospitals in the last 90 days of their life and had a high likelihood of dying in an acute hospital than in 281 
most other countries. These results suggest that Swiss patients might perceive longer 282 
hospitalisations and dying in hospital differently to other populations. There were also differences in 283 
DAH between cantons and between CAM and COM patients. Since the impact of the time spent in 284 
hospital for end-of-life care is, at least in part, financial, it will be important to establish whether 285 
such differences are supply or demand driven and whether or not lowering days spent in hospital at 286 
the end of life is likely to be favoured by patients. 287 
  288 
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TABLES 429 
Table 1: Descriptive statistics for the patients included in the study 430 
ACT, anti-cancer therapies; CAM, complementary/alternative medicine; ECO, basic hospital 431 
supplementary insurance (hospitalisation on general ward with free choice of hospital across 432 
Switzerland); SP+P, semi-private or private hospital supplementary insurance. 433 
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Table 2: Patient characteristics by canton 435 
Values in bold indicate highest cantonal result. 436 
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Table 3: Unadjusted values for days spent in acute care hospitals or other institutions during the last 90 days prior to death and percentage of patients 438 
dying in acute hospitals. DAH, days in hospital; DOI, days in other institutions; ACT, anti-cancer therapies; CAM, complementary alternative medicine; ECO, 439 
basic hospital supplementary insurance (hospitalisation on general ward with free choice of hospital acrross Switzerland); SP+P, semiprivate or private 440 
hospital supplementary insurance 441 
 442 
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Table 4: Univariable association (regression-based) between DAH and covariates. DAH, days in 443 
hospital; DOI, days in other institutions; ACT, anti-cancer therapies; CAM, complementary 444 
alternative medicine; ECO, basic hospital supplementary insurance (hospitalisation on general ward 445 
with free choice of hospital across Switzerland); SP+P, semiprivate or private hospital supplementary 446 
insurance 447 
 448 
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Table 5: Multivariable results for days spent in acute hospitals during the last 90 days prior to death. 450 
DAH, days in hospital; ACT, anti-cancer therapies; CAM, complementary alternative medicine; ECO, 451 
basic hospital supplementary insurance (hospitalisation on general ward with free choice of hospital 452 
across Switzerland); SP+P, semi-private or private hospital supplementary insurance. 453 
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FIGURES 455 
Figure 1: Descriptive statistics for patients who use or do not use complementary/alternative 456 
therapies. COM, conventional medicine only; CAM, complementary alternative medicine; ECO, basic 457 
hospital supplementary insurance (hospitalisation on general ward with free choice of hospital 458 
across Switzerland); SP+P, semi-private or private hospital supplementary insurance. 459 
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Figure 2: Relationship between age at death and days spent in acute hospitals or other institutions 461 
during the last 90 days prior to death. ○─○ = days spent in an acute hospital, ▪─▪ = days spent in 462 
other institutions, ⊥ T = 95% confidence intervals, bars show number of patients within the age 463 
group. 464 
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Figure 3: Estimated days spent in acute hospitals, results of the multivariable model for a patient 466 
with a mean age at death of 72.4 and a mean DOI of 5.4 days. DOI, days in other institutions; ACT, 467 
anti-cancer therapies; COM, conventional medicine only; CAM, complementary alternative 468 
medicine; F, female; M, male. — = mean, bars = 95% confidence intervals 469 
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